Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case Reuters Apr 9, 2025 Settlement resolves allegations Jazz delayed generic Xyrem launch, driving up costs for health plans and patients
Suven announces positive topline results from Phase-2 study of Samelisant for EDS in adult… EP News Bureau Oct 30, 2023 The study met primary endpoint, with Samelisant demonstrating statistically significant and clinically meaningful reduction in EDS…
Glenmark Pharma gets USFDA approval for Amphetamine Sulfate Tablets EP News Bureau Jan 28, 2021 The tablets are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, a sleeping disorder
